Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors

A method for preventing or treating schizophrenia, autism, Alzheimer's disease, bipolar disorders, Parkinson's disease, Huntington's disease, obesity, drug addiction or attention deficit/hyperactivity disorder in a mammal, which comprises administering an effective amount of a compound represented by the formula (I):

• wherein
• ring A represents an optionally substituted 6-membered ring,
• any one or two of from Z1 to Z4 represent —N═, and the others represent —CH═;
• Y represents an oxygen atom, a sulfur atom, an optionally substituted methylene group or —NRc—;
• Rc represents a hydrogen atom, or a substituent;
• and
• R represents
• (1) a group represented by the formula:
• wherein
• R1 represents a phenyl group or 5- to 10-membered heterocyclic group, each of which is optionally substituted;
• L represents a sulfur atom, an oxygen atom, an optionally substituted methylene group, —CO—, —NRa—, —CH2O—, —OCH2—, —NRaCOO—, —OCONRa—, —NRaCONRb—, —NRaCOCH2—, —CH2CONRa—, —NRaCO—, —CONRa—,
• Ra and Rb are the same or different and each represents a hydrogen atom, or an optionally substituted C1-6 alkyl group, or
• L and R1 in combination optionally form an optionally substituted bi- or tri-cyclic fused heterocyclic group;
• and
• ring B1 represents a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, each of which is optionally substituted;
• or
• (2) a group represented by the formula:
• wherein
• R2 represents a phenyl group or 5- to 10-membered heterocyclic group, each of which is optionally substituted;
• ring B2 represents a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, each of which is optionally substituted;
• and
• ring D represents an optionally further substituted 5- or 6-membered ring, or a salt thereof to a mammal.

Use of a compound represented by the formula (I):

• wherein
• ring A represents an optionally substituted 6-membered ring,
• any one or two of from Z1 to Z4 represent —N═, and the others represent —CH═;
• Y represents an oxygen atom, a sulfur atom, an optionally substituted methylene group or —NRc—;
• Rc represents a hydrogen atom, or a substituent;
• and
• R represents
• (1) a group represented by the formula:
• wherein
• R1 represents a phenyl group or 5- to 10-membered heterocyclic group, each of which is optionally substituted;
• L represents a sulfur atom, an oxygen atom, an optionally substituted methylene group, —CO—, —NRa—, —CH2O—, —OCH2—, —NRaCOO—, —OCONRa—, —NRaCONRb—, —NRaCOCH2—, —CH2CONRa—, —NRaCO—, —CONRa—,
• Ra and Rb are the same or different and each represents a hydrogen atom, or an optionally substituted C1-6 alkyl group, or
• L and R1 in combination optionally form an optionally substituted bi- or tri-cyclic fused heterocyclic group;
• and
• ring B1 represents a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, each of which is optionally substituted;
• or
• (2) a group represented by the formula:
• wherein
• R2 represents a phenyl group or 5- to 10-membered heterocyclic group, each of which is optionally substituted;
• ring B2 represents a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, each of which is optionally substituted;
• and
• ring D represents an optionally further substituted 5- or 6-membered ring, or a salt thereof for the production of an agent for preventing or treating schizophrenia, autism, Alzheimer's disease, bipolar disorders, Parkinson's disease, Huntington's disease, obesity, drug addiction or attention deficit/hyperactivity disorder.

A compound represented by the formula (I):

• wherein
• ring A represents an optionally substituted 6-membered ring,
• any one or two of from Z1 to Z4 represent —N═, and the others represent —CH═;
• Y represents an oxygen atom, a sulfur atom, an optionally substituted methylene group or —NRc—;
• Rc represents a hydrogen atom, or a substituent;
• and
• R represents
• (1) a group represented by the formula:
• wherein
• R1 represents a phenyl group or 5- to 10-membered heterocyclic group, each of which is optionally substituted;
• L represents a sulfur atom, an oxygen atom, an optionally substituted methylene group, —CO—, —NRa—, —CH2O—, —OCH2—, —NRaCOO—, —OCONRa—, —NRaCONRb—, —NRaCOCH2—, —CH2CONRa—, —NRaCO—, —CONRa—,
• Ra and Rb are the same or different and each represents a hydrogen atom, or an optionally substituted C1-6 alkyl group, or
• L and R1 in combination optionally form an optionally substituted bi- or tri-cyclic fused heterocyclic group;
• and
• ring B1 represents a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, each of which is optionally substituted;
• or
• (2) a group represented by the formula:
• wherein
• R2 represents a phenyl group or 5- to 10-membered heterocyclic group, each of which is optionally substituted;
• ring B2 represents a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring, each of which is optionally substituted;
• and
• ring D represents an optionally further substituted 5- or 6-membered ring, or a salt thereof for use in prevention or treatment of schizophrenia, autism, Alzheimer's disease, bipolar disorders, Parkinson's disease, Huntington's disease, obesity, drug addiction or attention deficit/hyperactivity disorder.